By
From the * Institut de Génétique et de Biologie Moléculaire et Cellulaire (CNRS/INSERM/ULP),
Strasbourg, 67404 Illkirch Cedex, France; and the Walter and Eliza Hall Institute for Medical
Research, Melbourne, Victoria 3050, Australia
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Little is known about the events triggering lymphocyte invasion of the pancreatic islets in prelude to autoimmune diabetes. For example, where islet-reactive T cells first encounter antigen has not been identified. We addressed this issue using BDC2.5 T cell receptor transgenic mice, which express a receptor recognizing a natural islet beta cell antigen. In BDC2.5 animals, activated T cells were found only in the islets and the lymph nodes draining them, and there was a close temporal correlation between lymph node T cell activation and islet infiltration. When naive BDC2.5 T cells were transferred into nontransgenic recipients, proliferating cells were observed only in pancreatic lymph nodes, and this occurred significantly before insulitis was detectable. Surprisingly, proliferation was not seen in 10-day-old recipients. This age-dependent dichotomy was reproduced in a second transfer system based on an unrelated antigen artificially expressed on beta cells. We conclude that beta cell antigens are transported specifically to pancreatic lymph nodes, where they trigger reactive T cells to invade the islets. Systemic or extrapancreatic T cell priming, indicative of activation via molecular mimicry or superantigens, was not seen. Compromised presentation of beta cell antigens in the pancreatic lymph nodes of juvenile animals may be the root of a first "checkpoint" in diabetes progression.
Key words: autoimmunity; antigen presentation; T lymphocytes; transgenic mice; nonobese diabetic ![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Insulin-dependent diabetes mellitus (IDDM)1 is caused by
autoimmune destruction of the insulin-producing beta
cells of the pancreatic islets of Langerhans (for reviews, see
references 1 and 2). Much of our current knowledge about
the complex pathogenesis of IDDM derives from studies
on the nonobese diabetic (NOD) mouse, which succumbs
to a disease closely resembling that of human patients (for a
review, see reference 3). These studies have revealed an influx of inflammatory cells into the islets, termed insulitis, starting at ~4-5 wk after birth; however, significant beta
cell destruction, and consequently diabetes, is not evident
until ~12 wk of age. Of the cells that constitute the insulitic lesion, T cells appear to play a primary role. Nonetheless, other cell typessuch as B cells, macrophages, and
dendritic cells (DCs)
also contribute to disease progression.
The events responsible for triggering IDDM in a susceptible individual are clouded in uncertainty. The role of environmental factors (4), the nature of the initiating inflammatory cell (7, 8), and the identity of the inciting antigen(s) (9) have all been vigorously debated. Among the important unresolved issues is where the initial stimulation of naive, islet-reactive T cells takes place. One possibility is that it occurs within the islets, where autoantigens are presented either by the beta cells that synthesize them or by APCs in the vicinity. This scenario might seem unlikely given the body of data establishing that naive T cells circulate through peripheral lymphoid organs rather than through tissues (12), but it could be that either the pancreatic islets or islet-reactive T cells are special in this respect. Another possible site of initial stimulation is in the LNs draining the pancreas. This is an attractive option because of its analogy to what happens when foreign proteins are introduced through the skin: antigen is captured by immature Langerhans cells, ferried to the draining LNs, and is presented there to recirculating naive T cells by the now-mature Langerhans cells (13). However, to date there is little experimental evidence of such a sequence of events in the progression of diabetes or, indeed, of any autoimmune disease. A third possibility is that potentially diabetogenic T cells are first stimulated systemically or at a distant site, either in a tissue or in one of the peripheral lymphoid organs. This proposed scenario reflects arguments that islet-reactive T cells are "awakened" upon activation by cross-reactive environmental antigens or microbial superantigens (5, 6).
To distinguish between these different possibilities, we
took advantage of the BDC2.5 TCR transgenic (tg) model
of diabetes (14). BDC2.5 tg mice carry the rearranged
TCR (V
1) and
(V
4) chain genes from a diabetogenic, beta cell-specific, CD4+ T cell clone isolated from a
diabetic NOD mouse (15, 16). T cells expressing the transgene-encoded receptor are efficiently selected on the
NOD background and contribute substantially to the peripheral T cell repertoire. Nevertheless, the autoreactive T
cells appear to ignore the beta cells for the first 2 wk of life. At that time, they abruptly invade the islets and insulitis progresses rapidly, such that at 3-4 wk of age almost all
islets are heavily infiltrated. Thus, the initiation of autoimmune attack is especially clear and synchronous in BDC2.5
mice, suggesting that this model might prove highly advantageous for studying the triggering of IDDM.
Here we present results from two types of experiments
monitoring T cell activity at different sites in prediabetic
BDC2.5/NOD tg mice, and tracking the behavior of naive
BDC2.5 T cells adoptively transferred into nontransgenic,
NOD-background hosts. The data prompt us to conclude
that diabetogenic T cells are first stimulated in the LNs immediately draining the pancreas, and that antigen availability
at this site is a critical determinant of disease initiation.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Mice.
The generation of BDC2.5/NOD TCR tg mice has been described previously (14, 17). CIsolation of Intraislet Lymphocytes.
The pancreatic LNs (PLNs) were removed, and the remaining pancreas tissue was carefully cut into small pieces using fine scissors. 5-10 islet infiltrates (easily identified in BDC2.5 pancreata as "bubbles" surrounding normal islet tissue) were hand-picked under a dissecting microscope, and converted into a single-cell suspension for flow cytometry analysis.Insulitis.
Thin sections from Bouin's solution-fixed, paraffin-embedded pancreas specimens were stained with hematoxylin-eosin and scored for insulitisAntibodies and Flow Cytometry.
T cell analysis was performed as described previously (21). The following mAbs were used: PE-conjugated CD4 (Caltag); biotin- or allophycoerythrin-conjugated CD8 (Caltag); FITC-conjugated CD69 (PharMingen); IM7, specific for CD44 (22); Mel14, specific for CD62L (23); and B20.1, specific for VCFSE Labeling and Adoptive Transfer.
For the BDC2.5 system, single-cell suspensions from pooled spleens were depleted of erythrocytes in 0.83% NH4Cl, adjusted to 107/ml in PBS, and incubated for 10 min at 37°C in the presence of 2.5 µM 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes) prepared as a 5 mM stock solution in DMSO. After incubation, the cells were washed twice with RPMI supplemented with 5% FCS, and adjusted to 108/ml. In each experiment, 200 µl (2 × 107 cells) were injected, intravenously for adult and intraperitoneally for 10-d-old recipients. These two routes of inoculation were comparable, since homing to the PLNs followed identical kinetics (data not shown). At various times after inoculation, LNs were removed and analyzed for the presence of CFSE- labeled cells. For the OT-I system (20, 25), single-cell suspensions from OT-I/RAG0 mice were depleted of CD24+ and CD4+ cells by treatment with J11d and RL-172 mAbs (26, 27) and complement. The proportion of OT-I cells was then determined by flow cytometry, staining for CD8 and V ![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
As a first step, we examined the activation status of T cells located at different
sites in the periphery of BDC2.5 TCR tg mice (Fig. 1).
Very few CD4+V4+ cells in the spleen and most LNs, including the inguinal (ILN) and mesenteric (MLN), expressed the activation marker CD69; in contrast, a large
proportion of cells in the PLNs and within the pancreatic
islets (intraislet lymphocytes, IILs) had an activated phenotype (Fig. 1 A). This activation was linked to the presence of the transgene, as these large populations of CD69+ cells
were not found in PLNs of nontransgenic littermates (data not shown). The activated PLN and IIL cells were similar
to each other and typical of other activated T cells in their
augmented expression of CD44 and diminished display of
CD62L (Fig. 1 B). These findings suggest that the antigen
that triggers BDC2.5 tg T cells is present specifically in the
pancreas and the immediately draining LNs. This notion was
supported by an analysis of TCR
chain usage by T cells
at the different sites: in the PLNs, cells expressing the endogenously encoded V
2 chain were underrepresented (and presumably those displaying the transgene-encoded
chain overrepresented), whereas the opposite was true in
other nodes, such as the ILNs (Fig. 1 C).
|
The presence of activated T cells in both the islets and draining LNs of BDC2.5 tg mice raised the question of whether they were first stimulated at the former site or at the latter. Priming may be quite synchronous in individual BDC2.5 animals as insulitis begins abruptly between days 15 and 18 after birth. Therefore, we performed a careful kinetic analysis, day by day beginning on day 12, scoring the percentage of CD69+ T cells in the PLNs versus the proportion of islets containing invading lymphocytes. As illustrated in Fig. 2, there was generally a good correlation between the fraction of activated PLN cells and infiltrated islets. On day 14, a few mice had CD69+ cells in the PLNs in the absence of detectable insulitis, but this was not a general observation. On the basis of these data, we concluded that activation of T cells in the PLNs and islet infiltration had a close temporal correlation, but could not establish conclusively which of the two was the primary event.
|
A possible reason for the inconclusive results in the preceding experiment is that, although it is considerably more synchronous than in standard NOD mice, the initiating event in BDC2.5 transgenics is still scattered over a window of 3 or 4 d in different individuals, rendering it difficult to precisely "capture" in a significant number of animals. Therefore, we switched to an adoptive transfer system, hoping that if the BDC2.5 T cells entered the circulation at exactly the same time in different animals, disease initiation would be highly synchronous. The transfer system is depicted in Fig. 3 A: splenocytes are removed from BDC2.5 tg mice, labeled in vitro with the cytoplasmic dye CFSE, and transferred into NOD-background recipients; some days later, different lymphoid organs are removed, and homing and proliferation are assayed by cytofluorimetric assessment of the presence and degree of dilution of CFSE staining. When CFSE-labeled cells proliferate, their fluorescence is distributed equally between the two daughter cells, resulting in a 2n-fold dilution in fluorescence intensity, where n represents the number of cell divisions.
|
Fig. 3 B presents histograms of CFSE staining in
CD4+V4+ cells from spleen and a variety of LNs 3 d after
transfer of splenocytes from a young, adult BDC2.5 mouse
into a young, adult C
0/NOD host. CFSE-labeled cells
were present in the spleen and the many LNs examined,
but only in the PLNs was there significant dilution of label,
signaling activation followed by proliferation. These data
from the transfer system closely mimic those derived from
regular BDC2.5 animals: the antigen that triggers BDC2.5 T cells is present in the LNs immediately draining the pancreas, but not in the other peripheral lymphoid organs examined.
It has been hypothesized that insulitis in NOD mice, in
particular infiltration of CD4+ T cells, requires initial islet
cell damage mediated by CD8+ T cells (7, 8, 28). In
our experiments, proliferating BDC2.5 T cells were found
in the PLNs of C0/NOD mice, which suggests that transport of the relevant autoantigen to this node does not require prior islet cell destruction by T cells displaying other
/
specificities. In fact, PLN-specific proliferation of
BDC2.5 cells was observed after transfer into standard
NOD, C
0/NOD, and RAG0/NOD hosts
to a similar
extent (Fig. 3 C) and with similar kinetics (data not
shown). Thus, other lymphocytes neither inhibit nor are
required for BDC2.5 cells to access their antigen in the PLNs.
We then exploited the
transfer system to address the question of whether naive
BDC2.5 T cells are first stimulated in the islets or in their
draining LNs. C0/NOD mice were used as recipients to
preclude interference from host
/
T cells and to simplify
the detection of transferred cells, particularly in the islets.
CFSE-labeled splenocytes from young, adult BDC2.5
transgenics were injected into nontransgenic C
0/NOD
recipients of similar age and, at various times after injection, the relevant LNs were removed for cytofluorimetric analysis, and pancreas sections were prepared for histological evaluation.
Results from a typical experiment are summarized in
Fig. 4. Already on day 1 after transfer, CFSE-labeled donor
cells appeared in both the PLNs and ILNs, but without
proliferation for the first 2 d. On day 3, PLN cells abruptly
exhibited strong dilution of the CFSE label, signifying proliferation, and staining levels gradually diminished over the
next 5 d. ILN cells showed no dilution of the CFSE label
on day 3, but a few cells with fully reduced staining could
be detected 1 d later, their low and uniform level of CFSE
indicative of recirculating cells. Substantial numbers of such
cells were found on day 5, and even more on day 8. Islet infiltration paralleled the appearance of recirculating cells in
the ILNs, though with some delaynot detectable on day
3, rare for the next 2 d, substantial only on day 8.
|
Clearly, then, proliferating cells emerged in the PLNs before the onset of islet invasion. A similar dissociation between the two events was seen in seven independent experiments.
The BDC2.5 Antigen Cannot Be Detected in the PLNs of Very Young NOD Mice.Previous studies have highlighted two "checkpoints" in the progression of disease in BDC2.5 TCR tg mice (14, 17, 35), and these seem to be characteristic of standard NOD mice as well (36). Checkpoint 1 concerns the onset of insulitis: even though BDC2.5 transgenics harbor plenty of T cells expressing an islet beta cell- reactive receptor from shortly after birth, invasion of the islets is not detectable until 15-18 d of age. In theory, this delay could reflect either T cell incompetence or antigen unavailability in the very young mice.
To evaluate the first explanation, we compared the ability of splenic T cells removed from 10-d-old and adult
BDC2.5 transgenics to proliferate in the PLNs after transfer
into adult C0/NOD hosts (Fig. 5 A). The T cells from
10-d-old mice appeared to be just as active as those from
adults, proliferating cells being detectable in the PLNs with
similar kinetics and to a similar degree. Thus, T cell incompetence is unlikely to be the explanation for the delayed
onset of insulitis.
|
To assess the second explanation, antigen unavailability,
we performed the reciprocal experiment, comparing the
ability of splenic T cells from adult BDC2.5 transgenics to
proliferate in the PLNs of 10-d-old and adult C0/NOD
recipients (Fig. 5 B). Here, there was a striking difference in behavior: as usual, proliferating T cells appeared in the
PLNs 3 d after transfer into adult hosts, but did not when
introduced into 10-d-old mice. These results argue that the
delayed onset of insulitis in BDC2.5 tg mice reflects unavailability of the autoantigen in juvenile animals.
We wondered whether reduced availability during the first weeks of life is particular
to the BDC2.5 antigen or can be generalized to other islet
cell antigens. Relevant data on a few other islet antigen/
TCR pairs have been reportedin all cases pertaining to a
viral protein artificially expressed on beta cells. In mice displaying influenza hemagglutinin on beta cells, activated hemagglutinin-specific T cells were found throughout the
peripheral lymphoid organs, and insulitis or diabetes could
occur before 3 wk of age (37). In animals synthesizing
SV40 T antigen in beta cells, activated T cells were confined to the PLNs, MLNs, and Peyer's patches, and could
be detected already 1 wk after birth (40). These findings argue that unavailability of islet antigens in juvenile animals may not be a general phenomenon. However, both systems
have complications: T cells recognizing hemagglutinin can
cross-react with murine self-antigens (41); SV40 T antigen
is an oncogene whose expression provokes hyperplasia, tumors, and probably cell damage (42). We sought to reexamine this issue with an antigen/TCR pair not known to
be subject to such complications.
RIP-mOVA tg mice express a membrane-bound form of OVA under the dictates of the insulin promoter, although significant amounts of OVA are made by both pancreatic islet beta cells and kidney proximal tubule cells; OT-I transgenics express the TCR genes from an MHC class I-restricted, OVA-specific T cell clone (20). When naive OT-I T cells were transferred into RIP-mOVA mice on the C57Bl/6 genetic background, proliferating CD8+ cells appeared specifically in the LNs draining the pancreas and kidney, the result of "cross-presentation" of the OVA epitope by bone marrow-derived (presumably dendritic) cells (20, 43). Thus, T cell activation in this system appeared to be nearly as specific as in the BDC2.5 system.
As expected, and as illustrated in Fig. 6, proliferating OT-I T cells were found in both the PLNs and renal LNs (RLNs) on day 3 after transfer into adult hosts. In contrast, no proliferating cells were detected in the PLNs after introduction into 10-d-old recipients, although they were observed in significant numbers in the RLNs of these animals. Thus, the inability of APCs in the PLNs of very young mice to trigger islet-reactive T cells is not antigen specific, does not depend on the class of MHC restricting element, and is not a peculiarity of the NOD genetic background. Interestingly, the defect is not a general property of LN APCs in juvenile animals, as those associated with the RLNs are quite competent.
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
This study focused on the events that trigger autoimmune attack of the pancreasin particular where and
when islet-reactive T cells first encounter antigen. Tackling
these questions was facilitated by the use of BDC2.5 TCR
tg mice, as the early events of diabetes pathogenesis are particularly clear and synchronous in these animals.
The first indication that
BDC2.5 T cells are initially stimulated in the vicinity of the
pancreas came from monitoring the activation state of T
cells at various sites in the periphery of prediabetic
BDC2.5/NOD tg mice. Activated cells (expressing high
levels of CD69 and CD44, and low levels of CD62L) were
found within the islets and PLNs, but not in the spleen or
in the many other LNs examined, including the MLNs
which drain the pancreas more distally (Fig. 1, A and B).
Results from the transfer system provided support for the
notion that BDC2.5 T cells are initially stimulated in the
pancreas surroundings (Fig. 3 B), and further established
that they encounter antigen first in the PLNs rather than
within the islets (Fig. 4). These findings argue strongly against a role for molecular mimicry in the BDC2.5 systemhad the initial stimulus been viral or dietary, we
should have seen activated/proliferating T cells at other locations, not strictly confined to the vicinity of the pancreas.
How does the BDC2.5 antigen arrive in the PLNs? A definitive answer to this question will probably not come until this antigen has been identified. At present, we know only that it is associated with the membrane fraction of beta cell vesicular structures (44), and that its presentation may depend on intact vesicles (our unpublished results). A likely possibility is that the antigen is picked up in the islets by immature DCs through phagocytosis or micropinocytosis, and is ferried to the PLNs via afferent lymphatic vessels, coincident with DC maturation. Certainly, DCs are present in early insulitic lesions, even before the arrival of lymphocytes (45). It is also possible that beta cell proteins are, themselves, transported to the PLNs through the afferent lymphatics, and it is there that the BDC2.5 antigen is taken up, processed, and presented. Incorporation of antigens into vesicles seems not to be necessary for effective transport to the PLNs because very diverse beta cell neoantigens appear to be presented in this node, such as membrane-bound OVA (20) and nuclear SV40 T antigen (40).
That beta cell antigens would be picked up by DCs in the islets, be ferried to the draining PLNs, be presented there to circulating naive T cells, and finally provoke those with anti-beta cell reactivity to invade the islets would be a sequence of events nicely analogous to the prevailing paradigm on antigen surveillance (13). As discussed below, this scenario is also consistent with the little existing data on standard NOD mice. It remains to fill in the many missing details.
The Time of Initial EncounterThe transfer system permitted us to address another critical issue concerning the events triggering autoimmune diabetes. Insulitis is not detectable in standard NOD mice before 4-6 wk of age, a delay classically considered to reflect the time it takes to activate islet-reactive T cells and expand them to high numbers. However, BDC2.5 TCR tg mice, with their enormous preformed antiislet repertoire, were found to exhibit a similar lag before the initiation of insulitis (14), prompting the speculation that diabetes progression is regulated, the transition to insulitis constituting a first checkpoint (14, 36). In theory, checkpoint 1 could reflect a deficiency in either T cell competence or antigen availability. To distinguish between the two, we performed crisscross transfer experiments, introducing 10-d-old or adult donor cells into adult hosts, as well as adult donors into 10-d-old or adult hosts. The defect appears to be in how antigen is made available, as both types of T cells proliferated in the PLNs after transfer into adult hosts (Fig. 5 A), whereas adult donors proliferated only in adult but not in 10-d-old hosts (Fig. 5 B, and data not shown).
Reduced availability of the BDC2.5 antigen in the PLNs
of very young mice could have several roots. One class of
explanations invokes the antigen itselfit may not be synthesized yet, may be made at too low a level, or may not be
in the appropriate state. The first possibility is ruled out by
the finding that preactivated, rather than naive, BDC2.5 T
cells can infiltrate the islets within days after transfer into
neonatal NOD recipients (48). However, this result does
not exclude the other two possibilities because activated T
cells can be stimulated by lower concentrations of antigen
than can naive cells (25), and because effective release to
the draining LNs could depend on antigen being in a particular form or subcellular compartment, e.g., part of a
multiprotein complex or encased within a vesicle. Evaluating these possibilities will require a comparison of the effective concentration of BDC2.5 antigen in the LNs of different-aged animals, possible through in vitro presentation
assays, but difficult and arduous given the scarcity of islets
in very young mice (our unpublished observations).
A second class of explanations for early BDC2.5 antigen
unavailability invokes the APCsit may be that the relevant antigen is perfectly available, but that the appropriate
APCs for ferrying it to or presenting it in the PLNs are at
fault. This immaturity may affect homing of DCs to the
pancreas, their ability to acquire antigens once there, or in
their traffic onwards to the PLNs. There is precedent for
defective APC function in neonates in other contexts (49,
50). Yet, our results suggest that the APC defect should be
a regional one, given that the RLNs of 10-d-old mOVA hosts were quite capable of supporting proliferation of transferred naive OT-I cells (Fig. 6), and the pancreas may thus
be somehow special. Perhaps different populations of DC
precursors reside in the pancreas and kidney of very young
animals, or perhaps there are different cytokine milieus in
the two organs, that in the pancreas being suboptimum for
DC mobilization (due, for example, to reduced levels of
TNF-
, GM-CSF, or IL-4 [13, 51]). The appearance of
DCs in the pancreas may require particular metabolic or endocrine changes occurring at that time (45). Refining the
transfer system by incorporating mutant or Ab-treated donors or hosts should aid us in distinguishing between these
various possibilities.
Whatever the explanation, the events underlying this transition are not specific to NOD mice, as checkpoint 1 is also observed when the BDC2.5 transgene is crossed onto the C57Bl/6 genetic background (17).
Generality.It is important to consider whether our conclusions about BDC2.5 T cells and the antigen they recognize are generalizable. The original BDC2.5 clone was isolated rather late in disease progression, from pooled spleen and LNs of a diabetic NOD female (15), so one might question its relevance to disease initiation. However, it has already been demonstrated that BDC2.5 T cells can engender full-blown diabetes in the absence of other lymphocytes (14), and we show here that no other lymphocytes are required for BDC2.5 cells to access their antigen in the PLNs (Fig. 3 C). It may also be worth noting that the BDC2.5 antigen has properties similar to the antigens recognized by several other mouse (44) and human (52) islet-reactive T cell clones. Nonetheless, it would be useful to compare the behavior of other diabetes-provoking antigens and the corresponding diabetogenic T cells at the time of disease initiation.
The little existing data on standard NOD mice are generally consistent with the observations on BDC2.5 TCR
transgenics. Three findings are in line with the notion that
initial stimulation of islet-reactive T cells occurs in the
PLNs: (a) alloxan-mediated destruction of the pancreas of
perinatal NOD animals prevented the emergence of potentially diabetogenic T cells, arguing against primary activation at extrapancreatic sites (53); (b) treating juvenile NOD
animals with anti-CD40 ligand or anti-7 integrin blocked
insulitis, but did not prevent the appearance of islet-reactive T cells, indicating that priming need not occur within
the islets (54, 55); and (c) DCs in the PLNs of NOD animals indeed seem to present islet-derived antigens (56). No
existing results favor or disfavor the idea that presentation
of beta cell antigens is compromised in the PLNs of standard NOD mice at a very young age, although there is
clear evidence of a checkpoint 1 at ~3 wk (36).
In conclusion, autoimmune diabetes in BDC2.5 TCR tg mice is initiated by developmentally regulated presentation of islet beta cell antigens in the PLNs, and this is most likely true for standard NOD mice. It will be interesting to see whether this phenomenon occurs in other autoimmune diseases as well.
![]() |
Footnotes |
---|
Address correspondence to Christophe Benoist and Diane Mathis, IGBMC, BP 163, 67404 Illkirch Cedex, France. Phone: 33-3-88-65-32-00; Fax: 33-3-88-65-32-46; E-mail: cb and dm{at}igbmc.u-strasbg.fr
Received for publication 11 September 1998 and in revised form 9 November 1998.
We thank the Diabetes Group for discussion, C. Carnaud for mice, C. Ebel for help with cytofluorimetric analyses, T. Ding for sections, J. Hergueux and P. Nathan for assistance, and P. Michel, F. Fischer, and V. Louerat for maintaining the mice.
This work was supported by institute funds from the Institut National de la Santé et de la Recherche Médicale, the Centre National de la Recherche Scientifique, the Hôpital Universitaire de Strasbourg, and Bristol-Myers Squibb, by grants from the Juvenile Diabetes Foundation International (to D. Mathis and C. Benoist), the EC-Biotech program (PL962151; to D. Mathis and C. Benoist), the National Health and Medical Research Council of Australia (to W. Heath), and the Cooperative Research Center for Vaccine Technology (to W. Heath). P. Höglund was supported by the Wenner-Gren Foundations.
Abbreviations used in this paper CFSE, 5,6-carboxyfluorescein diacetate succinimidyl ester; DC, dendritic cell; IDDM, insulin-dependent diabetes mellitus; IIL, intraislet lymphocyte; ILN, inguinal lymph node; MLN, mesenteric lymph node; NOD, nonobese diabetic; OT-I, OVA-specific CD8+ T cells; PLN, pancreatic lymph node; RAG, recombination activating gene; RIP, rat insulin promoter; RLN, renal lymph node; tg, transgenic.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Bach, J.F.. 1994. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr. Rev. 15: 516-542 [Abstract]. |
2. | Tisch, R., and H. McDevitt. 1996. Insulin-dependent diabetes mellitus. Cell. 85: 291-297 [Medline]. |
3. | Bach, J.F., and D. Mathis. 1997. 70th forum in immunology: the NOD mouse. Res. Immunol. 148: 285-286 [Medline]. |
4. | Leslie, R.D., and R.B. Elliott. 1994. Early environmental events as a cause of IDDM. Evidence and implications. Diabetes. 43: 843-850 [Abstract]. |
5. | Herrath, M.G., A. Holz, D. Homann, and M.B.A. Oldstone. 1998. Role of viruses in type I diabetes. Semin. Immunol. 10: 87-100 [Medline]. |
6. | Singh, B., S. Prange, and A.M. Jevnikar. 1998. Protective and destructive effects of microbial infection in insulin-dependent diabetes mellitus. Semin. Immunol. 10: 79-86 [Medline]. |
7. | Wong, F.S., and C.A. Janeway Jr.. 1997. The role of CD4 and CD8 T cells in type I diabetes in the NOD mouse. Res. Immunol. 148: 327-332 [Medline]. |
8. | Kay, T.W., H.L. Chaplin, J.L. Parker, L.A. Stephens, and H.E. Thomas. 1997. CD4+ and CD8+ T lymphocytes: clarification of their pathogenic roles in diabetes in the NOD mouse. Res. Immunol. 148: 320-327 [Medline]. |
9. | Nepom, G.T.. 1995. Glutamic acid decarboxylase and other autoantigens in IDDM. Curr. Opin. Immunol. 7: 825-830 [Medline]. |
10. | Roep, B.O.. 1996. T-cell responses to autoantigens in IDDM. The search for the Holy Grail. Diabetes. 45: 1147-1156 [Abstract]. |
11. | Wegmann, D.R.. 1996. The immune response to islets in experimental diabetes and insulin-dependent diabetes mellitus. Curr. Opin. Immunol. 8: 860-864 [Medline]. |
12. | Butcher, E.C., and L.J. Picker. 1996. Lymphocyte homing and homeostasis. Science. 272: 60-66 [Abstract]. |
13. | Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. Nature. 392: 245-252 [Medline]. |
14. | Katz, J.D., B. Wang, K. Haskins, C. Benoist, and D. Mathis. 1993. Following a diabetogenic T cell from genesis through pathogenesis. Cell. 74: 1089-1100 [Medline]. |
15. | Haskins, K., M. Portas, B. Bradley, D. Wegmann, and K.J. Lafferty. 1988. T-lymphocyte clone specific for pancreatic islet antigen. Diabetes. 37: 1444-1448 [Abstract]. |
16. | Haskins, K., and M. McDuffie. 1990. Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T-cell clone. Science. 249: 1433-1436 [Medline]. |
17. | Gonzalez, A., J.D. Katz, M.G. Mattei, H. Kikutani, C. Benoist, and D. Mathis. 1997. Genetic control of diabetes progression. Immunity. 7: 873-883 [Medline]. |
18. |
Philpott, K.L.,
J.L. Viney,
G. Kay,
S. Rastan,
E.M. Gardiner,
S. Chae,
A.C. Hayday, and
M.J. Owen.
1992.
Lymphoid development in mice congenitally lacking T cell receptor ![]() ![]() |
19. | Mombaerts, P., J. Iacomini, R.S. Johnson, K. Herrup, S. Tonegawa, and V.E. Papaioannou. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 68: 869-877 [Medline]. |
20. | Kurts, C., W.R. Heath, F.R. Carbone, J. Allison, J.F. Miller, and H. Kosaka. 1996. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184: 923-930 [Abstract]. |
21. | Cosgrove, D., D. Gray, A. Dierich, J. Kaufman, M. Lemeur, C. Benoist, and D. Mathis. 1991. Mice lacking MHC class II molecules. Cell. 66: 1051-1066 [Medline]. |
22. | Trowbridge, I.S., J. Lesley, R. Schuite, R. Human, and J. Trotter. 1982. Biochemical characterization and cellular distribution of a polymorphic, murine cell-surface glycoprotein expressed on lymph node cells. Immunogen. 15: 299-305 [Medline]. |
23. | Gallatin, W.M., I.L. Weissman, and E.C. Butcher. 1983. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature. 304: 30-34 [Medline]. |
24. |
Pircher, H.,
N. Rebai,
M. Groettrup,
C. Grégoire,
D.E. Speiser,
M.P. Happ,
E. Palmer,
R.M. Zinkernagel,
H. Hengartner, and
B. Malissen.
1992.
Preferential positive selection
of V![]() ![]() ![]() |
25. |
Kurts, C.,
J.F.A.P. Miller,
R.M. Subramanian,
F.R. Carbone, and
W.R. Heath.
1998.
MHC class I-restricted cross-presentation is biased towards high dose antigens and those
released during cellular destruction.
J. Exp. Med.
188:
409-414
|
26. |
Bruce, J.,
F.W. Symington,
T.J. McKearn, and
J. Sprent.
1981.
A monoclonal antibody discriminating between subsets
of T and B cells.
J. Immunol.
127:
2496-2501
|
27. | Ceredig, R., J.W. Lowenthal, M. Nabholz, and H.R. MacDonald. 1985. Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells. Nature. 314: 98-100 [Medline]. |
28. | Katz, J., C. Benoist, and D. Mathis. 1993. Major histocompatibility complex class I molecules are required for the development of insulitis in non-obese diabetic mice. Eur. J. Immunol. 23: 3358-3360 [Medline]. |
29. |
Wicker, L.S.,
E.H. Leiter,
J.A. Todd,
R.J. Renjilian,
E. Peterson,
P.A. Fischer,
P.L. Podolin,
M. Zijlstra,
R. Jaenisch, and
L.B. Peterson.
1994.
![]() |
30. | Serreze, D.V., E.H. Leiter, G.J. Christianson, D. Greiner, and D.C. Roopenian. 1994. Major histocompatibility complex class I-deficient NOD-B2mnull mice are diabetes and insulitis resistant. Diabetes. 43: 505-509 [Abstract]. |
31. |
Sumida, T.,
M. Furukawa,
A. Sakamoto,
T. Namekawa,
T. Maeda,
M. Zijlstra,
I. Iwamoto,
T. Koike,
S. Yoshida,
H. Tomioka, and
M. Taniguchi.
1994.
Prevention of insulitis
and diabetes in ![]() |
32. | Wang, B., A. Gonzalez, C. Benoist, and D. Mathis. 1996. The role of CD8+ T cells in initiation of insulin-dependent diabetes mellitus. Eur. J. Immunol. 26: 1762-1769 [Medline]. |
33. | Wong, F.S., I. Visintin, L. Wen, R.A. Flavell, and C.A. Janeway Jr.. 1996. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J. Exp. Med. 183: 67-76 [Abstract]. |
34. | Serreze, D.V., H.D. Chapman, D.S. Varnum, I. Gerling, E.H. Leiter, and L.D. Shultz. 1997. Initiation of autoimmune diabetes in NOD/Lt mice is MHC class I-dependent. J. Immunol. 158: 3978-3986 [Abstract]. |
35. |
Lühder, F.,
P. Höglund,
J.P. Allison,
C. Benoist, and
D. Mathis.
1998.
Cytotoxic T lymphocyte-associated antigen 4 regulates the unfolding of autoimmune diabetes.
J. Exp. Med.
187:
427-432
|
36. |
André, I.,
A. Gonzalez,
B. Wang,
J. Katz,
C. Benoist, and
D. Mathis.
1996.
Checkpoints in the progression of autoimmune disease: lessons from diabetes models.
Proc. Natl. Acad.
Sci. USA.
93:
2260-2263
|
37. | Scott, B., R. Liblau, S. Degermann, L.A. Marconi, L. Ogata, A.J. Caton, H.O. McDevitt, and D. Lo. 1994. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity. 1: 73-82 [Medline]. |
38. |
Sarukhan, A.,
A. Lanoue,
A. Franzke,
N. Brousse,
J. Buer, and
H. von Boehmer.
1998.
Changes in function of antigen-specific lymphocytes correlating with progression towards diabetes in a transgenic model.
EMBO (Eur. Mol. Biol. Organ.)
J.
17:
71-80
|
39. | Morgan, D.J., R. Liblau, B. Scott, S. Fleck, H.O. McDevitt, N. Sarvetnick, D. Lo, and L.A. Sherman. 1996. CD8+ T cell-mediated spontaneous diabetes in neonatal mice. J. Immunol. 157: 978-983 [Abstract]. |
40. | Forster, I., and I. Lieberam. 1996. Peripheral tolerance of CD4 T cells following local activation in adolescent mice. Eur. J. Immunol. 26: 3194-3202 [Medline]. |
41. | Bruno, L., H. von Boehmer, and J. Kirberg. 1996. Cell division in the compartment of naive and memory T lymphocytes. Eur. J. Immunol. 26: 3179-3184 [Medline]. |
42. | Adams, T.E., S. Alpert, and D. Hanahan. 1987. Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature. 325: 223-228 [Medline]. |
43. |
Heath, W.R.,
C. Kurts,
J.F.A.P. Miller, and
F.R. Carbone.
1998.
Cross-tolerance: a pathway for inducing tolerance to
peripheral tissue antigens.
J. Exp. Med.
187:
1549-1553
|
44. | Bergman, B., and K. Haskins. 1994. Islet-specific T-cell clones from the NOD mouse respond to beta-granule antigen. Diabetes. 43: 197-203 [Abstract]. |
45. |
Dahlen, E.,
K. Dawe,
L. Ohlsson, and
G. Hedlund.
1998.
Dendritic cells and macrophages are the first and major producers of TNF-alpha in pancreatic islets in the nonobese diabetic mouse.
J. Immunol.
160:
3585-3593
|
46. | Lo, D., C.R. Reilly, B. Scott, R. Liblau, H.O. McDevitt, and L.C. Burkly. 1993. Antigen-presenting cells in adoptively transferred and spontaneous autoimmune diabetes. Eur. J. Immunol. 23: 1693-1698 [Medline]. |
47. | Jansen, A., F. Homo-Delarche, H. Hooijkaas, P.J. Leenen, M. Dardenne, and H.A. Drexhage. 1994. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice. Diabetes. 43: 667-675 [Abstract]. |
48. | Katz, J.D., C. Benoist, and D. Mathis. 1995. T helper cell subsets in insulin-dependent diabetes. Science. 268: 1185-1188 [Medline]. |
49. | Lu, C.Y., E.G. Calamai, and E.R. Unanue. 1979. A defect in the antigen-presenting function of macrophages from neonatal mice. Nature. 282: 327-329 [Medline]. |
50. | Rafii-Tabar, E., and A.A. Czitrom. 1986. Ontogeny of priming of cytotoxic T cells to minor alloantigens: the development of direct priming precedes that of cross-priming. Eur. J. Immunol. 16: 1025-1027 [Medline]. |
51. |
Yang, X.-D.,
R. Tisch,
S.M. Singer,
Z.A. Cao,
R.S. Liblau,
R.D. Schreiber, and
H.O. McDevitt.
1994.
Effect of tumor
necrosis factor ![]() |
52. | Roep, B.O., S.D. Arden, R.R. de Vries, and J.C. Hutton. 1990. T-cell clones from a type-1 diabetes patient respond to insulin secretory granule proteins. Nature. 345: 632-634 [Medline]. |
53. | Larger, E., C. Becourt, J.F. Bach, and C. Boitard. 1995. Pancreatic islet beta cells drive T cell-immune responses in the nonobese diabetic mouse model. J. Exp. Med. 181: 1635-1642 [Abstract]. |
54. | Balasa, B., T. Krahl, G. Patstone, J. Lee, R. Tisch, H.O. McDevitt, and N. Sarvetnick. 1997. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J. Immunol. 159: 4620-4627 [Abstract]. |
55. | Yang, X.D., H.K. Sytwu, H.O. McDevitt, and S.A. Michie. 1997. Involvement of beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the development of diabetes in obese diabetic mice. Diabetes. 46: 1542-1547 [Abstract]. |
56. | Clare-Salzler, M., and Y. Mullen. 1992. Marked dendritic cell-T cell cluster formation in the pancreatic lymph node of the non-obese diabetic mouse. Immunology. 76: 478-484 [Medline]. |